CL2023003396A1 - Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos. - Google Patents

Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos.

Info

Publication number
CL2023003396A1
CL2023003396A1 CL2023003396A CL2023003396A CL2023003396A1 CL 2023003396 A1 CL2023003396 A1 CL 2023003396A1 CL 2023003396 A CL2023003396 A CL 2023003396A CL 2023003396 A CL2023003396 A CL 2023003396A CL 2023003396 A1 CL2023003396 A1 CL 2023003396A1
Authority
CL
Chile
Prior art keywords
treatment
extended
vegf antagonist
ocular disorders
angiogenic ocular
Prior art date
Application number
CL2023003396A
Other languages
English (en)
Spanish (es)
Inventor
L Vitti Robert
J Berliner Alyson
Chu Karen
Asmus Friedrich
Casimiro Da Silva Leal Sergio
EIßING THOMAS
D Rittenhouse Kay
Original Assignee
Regeneron Pharma
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Bayer Healthcare Llc filed Critical Regeneron Pharma
Publication of CL2023003396A1 publication Critical patent/CL2023003396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CL2023003396A 2021-05-17 2023-11-14 Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos. CL2023003396A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163189541P 2021-05-17 2021-05-17
US202163235398P 2021-08-20 2021-08-20
US202263297420P 2022-01-07 2022-01-07
US202263306315P 2022-02-03 2022-02-03

Publications (1)

Publication Number Publication Date
CL2023003396A1 true CL2023003396A1 (es) 2024-06-07

Family

ID=81975181

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2023003396A CL2023003396A1 (es) 2021-05-17 2023-11-14 Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos.
CL2024002972A CL2024002972A1 (es) 2021-05-17 2024-10-02 Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos.
CL2025001269A CL2025001269A1 (es) 2021-05-17 2025-04-29 Antagonistas del vegf en dosis alta para el tratamiento de trastornos oculares angiogénicos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2024002972A CL2024002972A1 (es) 2021-05-17 2024-10-02 Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos.
CL2025001269A CL2025001269A1 (es) 2021-05-17 2025-04-29 Antagonistas del vegf en dosis alta para el tratamiento de trastornos oculares angiogénicos.

Country Status (23)

Country Link
US (1) US20230302085A1 (https=)
EP (2) EP4647125A3 (https=)
JP (1) JP2024519629A (https=)
KR (1) KR20240008821A (https=)
AU (2) AU2022275786C1 (https=)
BR (1) BR112023023002A2 (https=)
CA (1) CA3190663A1 (https=)
CL (3) CL2023003396A1 (https=)
DK (1) DK4185318T3 (https=)
ES (1) ES3041647T3 (https=)
FI (1) FI4185318T3 (https=)
HR (1) HRP20251282T8 (https=)
IL (1) IL308505A (https=)
JO (1) JOP20230283A1 (https=)
LT (1) LT4185318T (https=)
MX (1) MX2023013554A (https=)
PE (1) PE20240922A1 (https=)
PL (1) PL4185318T3 (https=)
PT (1) PT4185318T (https=)
RS (1) RS67369B1 (https=)
SI (1) SI4185318T1 (https=)
TW (1) TW202313095A (https=)
WO (1) WO2022245739A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
IL315347A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
IL315374A (en) * 2022-03-15 2024-11-01 Regeneron Pharma Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121712520A (zh) * 2023-06-23 2026-03-20 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20190049934A (ko) * 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN117138171A (zh) 2017-12-13 2023-12-01 里珍纳龙药品有限公司 用于精确剂量输送的装置和方法
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use

Also Published As

Publication number Publication date
KR20240008821A (ko) 2024-01-19
BR112023023002A2 (pt) 2024-01-23
FI4185318T3 (fi) 2025-10-13
AU2022275786A8 (en) 2023-04-20
AU2022275786B2 (en) 2025-06-05
EP4185318B1 (en) 2025-09-03
JOP20230283A1 (ar) 2023-11-06
HRP20251282T8 (hr) 2025-12-19
MX2023013554A (es) 2023-11-29
PT4185318T (pt) 2025-09-29
CL2025001269A1 (es) 2025-08-22
EP4647125A3 (en) 2026-01-28
EP4185318A1 (en) 2023-05-31
PE20240922A1 (es) 2024-04-30
PL4185318T3 (pl) 2026-01-12
WO2022245739A1 (en) 2022-11-24
LT4185318T (lt) 2025-11-10
DK4185318T3 (da) 2025-09-29
SI4185318T1 (sl) 2025-10-30
HRP20251282T1 (hr) 2025-12-05
CA3190663A1 (en) 2022-11-24
IL308505A (en) 2024-01-01
EP4647125A2 (en) 2025-11-12
JP2024519629A (ja) 2024-05-21
RS67369B1 (sr) 2025-11-28
AU2022275786C1 (en) 2025-12-11
ES3041647T3 (en) 2025-11-13
AU2025226774A1 (en) 2025-09-25
TW202313095A (zh) 2023-04-01
CL2024002972A1 (es) 2025-01-24
US20230302085A1 (en) 2023-09-28
AU2022275786A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CL2023003396A1 (es) Regímenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogénicos.
MX2024011079A (es) Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
MX394875B (es) Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
CL2017001024A1 (es) Formulación de buprenorfina inyectable
CL2024002718A1 (es) Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2024002532A1 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
MX2021013516A (es) Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares.
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.
CO2024001004A2 (es) Compuestos de sulfonimidamida y usos de los mismos
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CR20190545A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2020014399A2 (es) Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida